Tirzepatide produces significantly more weight loss than semaglutide. In the first head-to-head trial comparing the two drugs, people taking tirzepatide lost 20.2% of their body weight over 72 weeks, compared to 13.7% for those on semaglutide. That’s roughly a 50% greater reduction, and the difference held up across other measures like waist circumference, where tirzepatide shrank waists by 18.4 cm versus 13.0 cm for semaglutide.
But “better” depends on what you’re optimizing for. Semaglutide has proven cardiovascular benefits that tirzepatide hasn’t matched yet, and the two drugs differ in how they work, what they cost, and what they’re approved to treat.
Weight Loss: What the Trials Show
The clearest comparison comes from the SURMOUNT-5 trial, which directly pitted tirzepatide (at 10 or 15 mg) against semaglutide (at 1.7 or 2.4 mg) in people with obesity and no diabetes. The results weren’t close. Tirzepatide was statistically superior for both weight loss and waist circumference reduction at 72 weeks.
Earlier placebo-controlled trials told a similar story, though comparing across separate studies is less precise. In those trials, 96% of people without diabetes taking tirzepatide at 10 mg lost at least 5% of their body weight by 72 weeks. For semaglutide at 2.4 mg, that number was 92% by 68 weeks. Among people with type 2 diabetes, the gap widened: 82% for tirzepatide versus 73% for semaglutide. These are strong numbers for both drugs, but tirzepatide consistently comes out ahead on the scale.
Why Tirzepatide Works Differently
Semaglutide mimics one gut hormone, GLP-1, which slows digestion, reduces appetite, and helps regulate blood sugar. Tirzepatide mimics two: GLP-1 and GIP. This dual action appears to be the key advantage. Research published in PNAS found that adding GIP activity to GLP-1 therapy improves insulin sensitivity through a mechanism that’s independent of weight loss itself, meaning the metabolic benefits aren’t just a downstream effect of losing pounds.
There’s also a subtlety in how tirzepatide interacts with the GLP-1 receptor. Unlike semaglutide, which activates the receptor in a way that causes it to become less responsive over time, tirzepatide triggers a different signaling pattern that leads to less of this desensitization. In practical terms, the receptor stays more responsive to the drug’s effects.
Side Effects Are Comparable
Given that tirzepatide is more potent for weight loss, you might expect it to cause worse side effects. It doesn’t, at least not in a meaningful way. A real-world comparison of gastrointestinal side effects across tirzepatide, semaglutide, and a third GLP-1 drug (dulaglutide) found that all three carried comparable risks. The rates of nausea, vomiting, and other GI problems were essentially the same across all three medications.
Both drugs cause the most nausea during the dose-escalation period, when the body is adjusting to the medication. For both, symptoms typically ease once you reach a stable dose. The titration schedules are structured to minimize this: semaglutide starts at 0.25 mg weekly and increases by 0.25 mg every four weeks until reaching the target of 2.4 mg over 16 to 20 weeks. Tirzepatide starts at 2.5 mg and increases by 2.5 mg every four weeks, up to a maximum of 15 mg.
Semaglutide Has a Cardiovascular Edge
This is where semaglutide pulls ahead. The SELECT trial demonstrated that semaglutide (sold as Wegovy for weight management) reduced the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death. Events occurred in 6.5% of participants on Wegovy compared to 8% on placebo. Based on these results, the FDA approved Wegovy as the first weight loss medication specifically indicated to reduce serious heart problems in adults with obesity or overweight.
Tirzepatide has no equivalent cardiovascular outcome data yet. Its cardiovascular outcomes trial is underway, but until those results are published, semaglutide is the only option in this class with a proven heart benefit. For someone whose primary concern is cardiovascular risk rather than maximum weight loss, that distinction matters.
FDA Approvals and Brand Names
Both drugs are sold under different brand names depending on the condition being treated. Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management (approved November 2023). Semaglutide is sold as Ozempic for diabetes and Wegovy for weight loss, with an oral form called Rybelsus also available for diabetes.
All of these require a prescription. Your doctor may prescribe one over the other based on your insurance coverage, existing health conditions, and treatment goals. Someone with type 2 diabetes and obesity might be prescribed either one, while someone primarily seeking cardiovascular risk reduction would likely be steered toward Wegovy.
How Costs Compare
At list price, both medications are expensive and surprisingly close in cost. Zepbound (tirzepatide for weight loss) lists at about $1,060 per month, while Wegovy (semaglutide for weight loss) lists at roughly $1,349 per month. On the diabetes side, Mounjaro lists at about $1,080 per month and Ozempic at about $998 per month.
These are list prices before insurance, and what you actually pay varies enormously depending on your plan, your diagnosis, and manufacturer savings programs. Insurance coverage for weight management indications remains inconsistent. Many plans cover these drugs for diabetes but not for obesity alone, which can make the out-of-pocket difference between the two less about list price and more about which one your insurer happens to cover.
Which One Is Right for You
If your primary goal is losing as much weight as possible, tirzepatide has a clear edge. A 20% average body weight reduction at 72 weeks is substantially better than 14%, and the side effect profiles are similar enough that tolerability isn’t a meaningful differentiator. If you have cardiovascular disease or high cardiovascular risk, semaglutide’s proven ability to reduce heart attacks and strokes gives it an advantage that tirzepatide can’t claim yet. And if cost or insurance coverage is the deciding factor, whichever drug your plan covers at a lower copay may be the practical winner regardless of clinical differences.
Both medications represent a significant advance over older weight loss treatments. The honest answer to “is tirzepatide better” is that it produces more weight loss with similar side effects, but semaglutide has broader proven benefits and a longer track record. The best choice depends on what “better” means for your specific situation.